Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases.

Journal of personalized medicine

Jin S, Kostka K, Posada JD, Kim Y, Seo SI, Lee DY, Shah NH, Roh S, Lim YH, Chae SG, Jin U, Son SJ, Reich C, Rijnbeek PR, Park RW, You SC.
PMID: 33352870
J Pers Med. 2020 Dec 18;10(4). doi: 10.3390/jpm10040288.

Incident depression has been reported to be associated with poor prognosis in patients with cardiovascular disease (CVD), which might be associated with beta-blocker therapy. Because early detection and intervention can alleviate the severity of depression, we aimed to develop...

Cite
Jin S, Kostka K, Posada JD, et al. Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases. J Pers Med. 2020;10(4)doi: 10.3390/jpm10040288.
Jin, S., Kostka, K., Posada, J. D., Kim, Y., Seo, S. I., Lee, D. Y., Shah, N. H., Roh, S., Lim, Y. H., Chae, S. G., Jin, U., Son, S. J., Reich, C., Rijnbeek, P. R., Park, R. W., & You, S. C. (2020). Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases. Journal of personalized medicine, 10(4), . https://doi.org/10.3390/jpm10040288
Jin, Suho, et al. "Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases." Journal of personalized medicine vol. 10,4 (2020). doi: https://doi.org/10.3390/jpm10040288
Jin S, Kostka K, Posada JD, Kim Y, Seo SI, Lee DY, Shah NH, Roh S, Lim YH, Chae SG, Jin U, Son SJ, Reich C, Rijnbeek PR, Park RW, You SC. Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases. J Pers Med. 2020 Dec 18;10(4). doi: 10.3390/jpm10040288. PMID: 33352870; PMCID: PMC7766565.
Copy Download .nbib Format: NLM
Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs.

Intensive care medicine experimental

Aboab J, Mayaud L, Sebille V, de Oliveira R, Jourdain M, Annane D.
PMID: 29974363
Intensive Care Med Exp. 2018 Jul 04;6(1):14. doi: 10.1186/s40635-018-0178-1.

BACKGROUND: There is an increasing interest in beta-blockade as a therapeutic approach to sepsis following consistent experimental findings of attenuation of inflammation and improved survival with beta1 selective antagonist. However, the mechanism of these beneficial effects remains very uncertain....

Cite
Aboab J, Mayaud L, Sebille V, et al. Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs. Intensive Care Med Exp. 2018;6(1):14doi: 10.1186/s40635-018-0178-1.
Aboab, J., Mayaud, L., Sebille, V., de Oliveira, R., Jourdain, M., & Annane, D. (2018). Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs. Intensive care medicine experimental, 6(1), 14. https://doi.org/10.1186/s40635-018-0178-1
Aboab, Jerome, et al. "Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs." Intensive care medicine experimental vol. 6,1 (2018): 14. doi: https://doi.org/10.1186/s40635-018-0178-1
Aboab J, Mayaud L, Sebille V, de Oliveira R, Jourdain M, Annane D. Esmolol indirectly stimulates vagal nerve activity in endotoxemic pigs. Intensive Care Med Exp. 2018 Jul 04;6(1):14. doi: 10.1186/s40635-018-0178-1. PMID: 29974363; PMCID: PMC6031554.
Copy Download .nbib Format: NLM
Dermatological adverse effects of anti-glaucoma eye drops: a review.

Journal of the European Academy of Dermatology and Venereology : JEADV

Patchinsky A, Petitpain N, Gillet P, Angioi-Duprez K, Schmutz JL, Bursztejn AC.
PMID: 35032359
J Eur Acad Dermatol Venereol. 2022 Jan 15; doi: 10.1111/jdv.17928. Epub 2022 Jan 15.

Many patients are treated for glaucoma. Like other drugs, anti-glaucoma eye drops may induce dermatological adverse effects. We aim to review the dermatological adverse effects secondary to the active agents in anti-glaucoma eye drops through a literature review. In...

Cite
Patchinsky A, Petitpain N, Gillet P, et al. Dermatological adverse effects of anti-glaucoma eye drops: a review. J Eur Acad Dermatol Venereol. 2022;doi: 10.1111/jdv.17928.
Patchinsky, A., Petitpain, N., Gillet, P., Angioi-Duprez, K., Schmutz, J. L., & Bursztejn, A. C. (2022). Dermatological adverse effects of anti-glaucoma eye drops: a review. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17928
Patchinsky, Alexandra, et al. "Dermatological adverse effects of anti-glaucoma eye drops: a review." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2022). doi: https://doi.org/10.1111/jdv.17928
Patchinsky A, Petitpain N, Gillet P, Angioi-Duprez K, Schmutz JL, Bursztejn AC. Dermatological adverse effects of anti-glaucoma eye drops: a review. J Eur Acad Dermatol Venereol. 2022 Jan 15; doi: 10.1111/jdv.17928. Epub 2022 Jan 15. PMID: 35032359.
Copy Download .nbib Format: NLM
[Pharmacological treatment of obesity].

Anales del sistema sanitario de Navarra

Salvador J, Silva C, Santos E.
PMID: 12861278
An Sist Sanit Navar. 2002;25:143-61. doi: 10.23938/ASSN.0822.

The foundation on which the treatment of obesity rests is made up of the procedures aimed at unbalancing the equation of energy balance in favour of calorie consumption. Pharmacological treatment is aimed at favouring a reduction of calorie intake...

Cite
Salvador J, Silva C, Santos E. Tratamiento farmacológico de la obesidad. [Pharmacological treatment of obesity]. An Sist Sanit Navar. 2002;25:143-61doi: 10.23938/ASSN.0822.
Salvador, J., Silva, C., & Santos, E. (2002). Tratamiento farmacológico de la obesidad. [Pharmacological treatment of obesity]. Anales del sistema sanitario de Navarra, 25143-61. https://doi.org/10.23938/ASSN.0822
Salvador, J, et al. "Tratamiento farmacológico de la obesidad." [Pharmacological treatment of obesity]. Anales del sistema sanitario de Navarra vol. 25 (2002): 143-61. doi: https://doi.org/10.23938/ASSN.0822
Salvador J, Silva C, Santos E. Tratamiento farmacológico de la obesidad. [Pharmacological treatment of obesity]. An Sist Sanit Navar. 2002;25:143-61. doi: 10.23938/ASSN.0822. Spanish. PMID: 12861278.
Copy Download .nbib Format: NLM
Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report.

Frontiers in endocrinology

Hakami YA.
PMID: 26347710
Front Endocrinol (Lausanne). 2015 Aug 18;6:123. doi: 10.3389/fendo.2015.00123. eCollection 2015.

Parathyroid (PTH) exploration surgery carries the risk of developing post-operative thyroiditis due to vigorous manual manipulation of the thyroid gland during surgery. Post-operative thyroiditis has a wide spectrum of clinical manifestations. However, it remains underreported. Here, we describe a...

Cite
Hakami YA. Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report. Front Endocrinol (Lausanne). 2015;6:123doi: 10.3389/fendo.2015.00123.
Hakami, Y. A. (2015). Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report. Frontiers in endocrinology, 6123. https://doi.org/10.3389/fendo.2015.00123
Hakami, Yasser Ali. "Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report." Frontiers in endocrinology vol. 6 (2015): 123. doi: https://doi.org/10.3389/fendo.2015.00123
Hakami YA. Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report. Front Endocrinol (Lausanne). 2015 Aug 18;6:123. doi: 10.3389/fendo.2015.00123. eCollection 2015. PMID: 26347710; PMCID: PMC4539555.
Copy Download .nbib Format: NLM
Beta-adrenergic blocking drugs in breast cancer: a perspective review.

Therapeutic advances in medical oncology

Barron TI, Sharp L, Visvanathan K.
PMID: 22590485
Ther Adv Med Oncol. 2012 May;4(3):113-25. doi: 10.1177/1758834012439738.

The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved...

Cite
Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012;4(3):113-25doi: 10.1177/1758834012439738.
Barron, T. I., Sharp, L., & Visvanathan, K. (2012). Beta-adrenergic blocking drugs in breast cancer: a perspective review. Therapeutic advances in medical oncology, 4(3), 113-25. https://doi.org/10.1177/1758834012439738
Barron, Thomas I, et al. "Beta-adrenergic blocking drugs in breast cancer: a perspective review." Therapeutic advances in medical oncology vol. 4,3 (2012): 113-25. doi: https://doi.org/10.1177/1758834012439738
Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012 May;4(3):113-25. doi: 10.1177/1758834012439738. PMID: 22590485; PMCID: PMC3349076.
Copy Download .nbib Format: NLM
Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting.

Pharmacy practice

Schimmer JJ, Billups SJ, Delate T.
PMID: 25136395
Pharm Pract (Granada). 2009 Oct;7(4):205-12. doi: 10.4321/s1886-36552009000400003. Epub 2009 Mar 15.

OBJECTIVE: To evaluate beta blocker persistence six months after beta-blocker initiation or dose titration in heart failure (HF) patients with COPD compared to those without COPD. Secondary objectives included comparison of beta-blocker dose achieved, changes in left ventricular ejection...

Cite
Schimmer JJ, Billups SJ, Delate T. Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharm Pract (Granada). 2009;7(4):205-12doi: 10.4321/s1886-36552009000400003.
Schimmer, J. J., Billups, S. J., & Delate, T. (2009). Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharmacy practice, 7(4), 205-12. https://doi.org/10.4321/s1886-36552009000400003
Schimmer, Jennifer J, et al. "Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting." Pharmacy practice vol. 7,4 (2009): 205-12. doi: https://doi.org/10.4321/s1886-36552009000400003
Schimmer JJ, Billups SJ, Delate T. Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharm Pract (Granada). 2009 Oct;7(4):205-12. doi: 10.4321/s1886-36552009000400003. Epub 2009 Mar 15. PMID: 25136395; PMCID: PMC4134838.
Copy Download .nbib Format: NLM
Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database.

Korean circulation journal

Won H, Suh Y, Kim GS, Ko YG, Hong MK.
PMID: 32096355
Korean Circ J. 2020 Jun;50(6):499-508. doi: 10.4070/kcj.2019.0231. Epub 2020 Jan 06.

BACKGROUND AND OBJECTIVES: Whether beta blockers favorably impact the clinical outcome in patients with acute myocardial infarction (AMI) remains in debate. We investigated the impact of beta blocker on major clinical outcomes during 2 years after percutaneous coronary intervention...

Cite
Won H, Suh Y, Kim GS, et al. Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database. Korean Circ J. 2020;50(6):499-508doi: 10.4070/kcj.2019.0231.
Won, H., Suh, Y., Kim, G. S., Ko, Y. G., & Hong, M. K. (2020). Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database. Korean circulation journal, 50(6), 499-508. https://doi.org/10.4070/kcj.2019.0231
Won, Hoyoun, et al. "Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database." Korean circulation journal vol. 50,6 (2020): 499-508. doi: https://doi.org/10.4070/kcj.2019.0231
Won H, Suh Y, Kim GS, Ko YG, Hong MK. Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database. Korean Circ J. 2020 Jun;50(6):499-508. doi: 10.4070/kcj.2019.0231. Epub 2020 Jan 06. PMID: 32096355; PMCID: PMC7234850.
Copy Download .nbib Format: NLM
Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction.

Chonnam medical journal

Kim HK, Lim KS, Kim SS, Na JY.
PMID: 34123741
Chonnam Med J. 2021 May;57(2):132-138. doi: 10.4068/cmj.2021.57.2.132. Epub 2021 May 24.

Following acute myocardial infarction (AMI), early use of beta-blockers (BBs) reduced the incidences of ventricular arrhythmia (VA) and death in the pre reperfusion era. However, some studies have reported a worsening of clinical outcomes and therefore, this study used...

Cite
Kim HK, Lim KS, Kim SS, et al. Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction. Chonnam Med J. 2021;57(2):132-138doi: 10.4068/cmj.2021.57.2.132.
Kim, H. K., Lim, K. S., Kim, S. S., & Na, J. Y. (2021). Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction. Chonnam medical journal, 57(2), 132-138. https://doi.org/10.4068/cmj.2021.57.2.132
Kim, Hyun Kuk, et al. "Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction." Chonnam medical journal vol. 57,2 (2021): 132-138. doi: https://doi.org/10.4068/cmj.2021.57.2.132
Kim HK, Lim KS, Kim SS, Na JY. Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction. Chonnam Med J. 2021 May;57(2):132-138. doi: 10.4068/cmj.2021.57.2.132. Epub 2021 May 24. PMID: 34123741; PMCID: PMC8167445.
Copy Download .nbib Format: NLM
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.

Cancer medicine

Lee M, Chung WB, Lee JE, Park CS, Park WC, Song BJ, Youn HJ.
PMID: 33998163
Cancer Med. 2021 Jun;10(12):3964-3973. doi: 10.1002/cam4.3956. Epub 2021 May 16.

BACKGROUND: There is no proven primary preventive strategy for doxorubicin-induced subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) risk. We investigated the primary preventive effect on DISC of the concomitant use of angiotensin receptor blockers (ARBs) or...

Cite
Lee M, Chung WB, Lee JE, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021;10(12):3964-3973doi: 10.1002/cam4.3956.
Lee, M., Chung, W. B., Lee, J. E., Park, C. S., Park, W. C., Song, B. J., & Youn, H. J. (2021). Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer medicine, 10(12), 3964-3973. https://doi.org/10.1002/cam4.3956
Lee, Myunhee, et al. "Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin." Cancer medicine vol. 10,12 (2021): 3964-3973. doi: https://doi.org/10.1002/cam4.3956
Lee M, Chung WB, Lee JE, Park CS, Park WC, Song BJ, Youn HJ. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021 Jun;10(12):3964-3973. doi: 10.1002/cam4.3956. Epub 2021 May 16. PMID: 33998163; PMCID: PMC8209607.
Copy Download .nbib Format: NLM
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.

Circulation

McMurray JJV, Packer M.
PMID: 33378214
Circulation. 2021 Mar 02;143(9):875-877. doi: 10.1161/CIRCULATIONAHA.120.052926. Epub 2020 Dec 30.

No abstract available.

Cite
McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2020;143(9):875-877doi: 10.1161/CIRCULATIONAHA.120.052926.
McMurray, J. J. V., & Packer, M. (2021). How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation, 143(9), 875-877. https://doi.org/10.1161/CIRCULATIONAHA.120.052926
McMurray, John J V, and Packer, Milton. "How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine." Circulation vol. 143,9 (2021): 875-877. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.052926
McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2021 Mar 02;143(9):875-877. doi: 10.1161/CIRCULATIONAHA.120.052926. Epub 2020 Dec 30. PMID: 33378214.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries